Market Cap
$25.7B
DGX
QUEST DIAGNOSTICS INC
$231.36 ▲ +0.12%
Prev close $231.09Market cap$25.7B
ConsensusHold
12-mo target$247.73 (+7.1%)
▲ Bullish
Analyst conviction 6/10
Insider Selling Cluster (2 insiders)High Impact Filing (7/10)35 New Institutional Positions15 Institutional Exits Healthcare & Medical Devices
Snapshot
The big-picture read on DGX right now — valuation, ownership and activity at a glance.
Cap Size
Large Cap
Analyst Consensus
Buy (57%)
Inst. Holders
50 funds
Inst. Value
$16.2B
Inst. Activity
35 buys / 15 sells
Insider Activity
$0.00 buy / $14.4M sell
Insider Net $
-$14.4M
Social Sentiment
55° Neutral
SEC Reports
9
Congressional
4 trades
Price chart 30d -3.9%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 22, 2026 earnings
Sep 9, 2026 SEC Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026
SECAUCUS, N.J., Sept. 22, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader
Quest Diagnostics reported Q2 2026 EPS of $3.12, a 9.0% beat vs the $2.86 consensus, and announced a partnership with Ap
PRESS-RELEASE — Impact 6/10
Two senior insiders at Quest Diagnostics sold a combined $6.32M in open-market transactions over a 7-day window, includi
CLUSTER — Impact 3/10
Sep 1, 2026 Insider
Davis J. E. sold 10,000 shares
CEO and President @ $242.72 ($2.4M)
Aug 28, 2026 Insider
PREVOZNIK MICHAEL E acquired via exercise 22,677 shares
SVP & General Counsel @ $112.17 ($2.5M)
Aug 28, 2026 Insider
Jul 23, 2026 SEC PREVOZNIK MICHAEL E sold 16,010 shares
SVP & General Counsel @ $242.88 ($3.9M)
Quest Diagnostics reported Q2 2026 adjusted EPS of $3.12, beating consensus of $2.82 by 10.6%, and revenue of $3.04B, be
8-K — Impact 7/10
Jun 30, 2026 Inst.
NORGES BANK — NEW
1,406,620 shares ($298.1M)
Analyst ratings buy % +14.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
57% rate it Buy or better · 23 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 21, 2026 | Truist Securities | MAINTAIN | Hold | 55% |
| Sep 8, 2026 | UBS | MAINTAIN | Neutral | 55% |
| Jul 28, 2026 | JP Morgan | MAINTAIN | Neutral | 55% |
| Jul 25, 2026 | UBS | MAINTAIN | Neutral | 55% |
| Jul 24, 2026 | Mizuho | MAINTAIN | Outperform | 52% |
| Jul 24, 2026 | Truist Securities | MAINTAIN | Hold | 55% |
| Jul 24, 2026 | Barclays | MAINTAIN | Overweight | 54% |
| Jul 24, 2026 | Baird | MAINTAIN | Neutral | 54% |
| Jul 13, 2026 | Baird | MAINTAIN | Neutral | 54% |
| Apr 22, 2026 | UBS | MAINTAIN | Neutral | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 6 | 7 | 10 | 0 | 0 | 57% | |
| Aug 1, 2026 | 6 | 7 | 10 | 0 | 0 | 57% | |
| Jul 1, 2026 | 6 | 7 | 10 | 0 | 0 | 57% | |
| Jun 1, 2026 | 6 | 7 | 11 | 0 | 0 | 54% | |
| May 1, 2026 | 6 | 7 | 11 | 0 | 0 | 54% | |
| Apr 1, 2026 | 6 | 7 | 11 | 0 | 0 | 54% | |
| Mar 1, 2026 | 6 | 7 | 11 | 0 | 0 | 54% | |
| Feb 1, 2026 | 6 | 7 | 11 | 0 | 0 | 54% |
Price targets
Where 15 covering analysts think DGX trades over the next 12 months.
$247.73 +7.1% upside Buy
Current$231.36 Low$204.00 Median$250.00 High$265.00 15 analysts
$204.00$265.00
Analyst rating Buy· 2.1/5 as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
55°
Neutral
BearishNeutralBullish
Recent posts
$IREN releases “What Will You Build Next?” Infrastructure Behind AI Agents Ad
▲ 1 · 💬 1· ⚡ 0.5
Enterprise DePIN Infrastructure: Managed NVIDIA DGX A100 Distributed Node Fleets for High-Density AI Workloads
▲ 0 · 💬 0
Enterprise DePIN Infrastructure: Managed NVIDIA DGX A100 Distributed Node Fleets for High-Density AI Workloads
▲ 1 · 💬 0· ⚡ 0.5
Church of AI --- Tax Free Data Centers
▲ 1 · 💬 1· ⚡ 0.5
Intel Announces Xeon 6 Being Used As Processor For NVIDIA DGX Rubin NVL8 Systems
▲ 1 · 💬 0· ⚡ 0.5
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
9 SEC filing reports analyzed · 3 bullish, 1 bearish, 0 mixed, 5 neutral · avg impact 4.6/10.
BULLISHPRESS-RELEASE6/10
Quest Diagnostics reported Q2 2026 EPS of $3.12, a 9.0% beat vs the $2.86 consensus, and announced a
Sep 9, 2026
NEUTRALCLUSTER3/10
Two senior insiders at Quest Diagnostics sold a combined $6.32M in open-market transactions over a 7
Sep 4, 2026
BULLISH8-K7/10
Quest Diagnostics reported Q2 2026 adjusted EPS of $3.12, beating consensus of $2.82 by 10.6%, and r
Jul 23, 2026
NEUTRALCOURT-RULING2/10
The court denied plaintiff's motion to remand a data breach class action against Quest Diagnostics t
Jul 3, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 22, 2026
earnings
Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026
SECAUCUS, N.J., Sept. 22, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced toda
Sep 15, 2026
short_volume
Short Volume: DGX — 66.9% short (0.5M / 0.7M)
Short: 459,467 | Exempt: 3 | TRF Vol: 686,463 | Short Ratio: 66.9% | Off-exchange volume (dark pool + OTC)
Sep 10, 2026
short_volume
Short Volume: DGX — 63.6% short (0.3M / 0.5M)
Short: 342,328 | Exempt: 5 | TRF Vol: 538,188 | Short Ratio: 63.6% | Off-exchange volume (dark pool + OTC)
Sep 9, 2026
earnings
Apple Health app Users to be Able to Order Labs from Quest Diagnostics
Coming later this year, Apple Health app users will be able to conveniently and securely purchase and receive results of Quest's biomarker lab testing
Sep 7, 2026
dark_pool
Dark Pool: DGX — 1.4M shares, 37,246 trades
Week starting 2026-09-07. Total ATS volume: 1,369,588 shares across 37,246 trades.
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $2.86 | $2.82–$2.91 | 10.1% | +0.0% | 11↑ 1↓ | $3.0B | 13 |
| Next Q | $2.68 | $2.61–$2.74 | 10.7% | +0.0% | 11↑ 1↓ | $3.0B | 13 |
| Current FY | $11.19 | $11.12–$11.49 | 13.6% | -0.0% | 15↑ 0↓ | $12.0B | 16 |
| Next FY | $12.06 | $11.82–$12.56 | 7.8% | +0.0% | 16↑ 0↓ | $12.6B | 16 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $2.863 | — |
| 7d ago | $2.863 | — |
| 30d ago | $2.863 | — |
| 60d ago | $2.863 | — |
| 90d ago | $2.801 | +0.062 |
Institutional ownership
Which big funds own DGX (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $16.2B total value (76,537,634 shares) as of 2026-Q2. Top holders: Erste, BlackRock,, VANGUARD. Net buying activity: 35 institutions added/increased vs 15 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| Erste Asset Management GmbH | 0 | $0.00 | 0.0% | — |
| BlackRock, Inc. | 9,275,411 | $2.0B | 12.1% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 7,233,394 | $1.5B | 9.5% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 6,131,045 | $1.3B | 8.0% | — |
| STATE STREET CORP | 5,516,643 | $1.2B | 7.2% | — |
| Boston Partners | 4,744,473 | $1.0B | 6.2% | — |
| JPMORGAN CHASE & CO | 3,520,438 | $748.6M | 4.6% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 3,137,873 | $662.6M | 4.1% | — |
| MORGAN STANLEY | 2,460,497 | $521.5M | 3.2% | — |
| EdgePoint Investment Group Inc. | 2,247,568 | $476.4M | 2.9% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| NORGES BANK | NEW | — | 1,406,620 | — | $298.1M |
| FMR LLC | ADD | 942,218 | 1,398,735 | +48.5% | $296.5M |
| GOLDMAN SACHS GROUP INC | TRIM | 1,348,694 | 982,694 | -27.1% | $208.3M |
| UBS Group AG | ADD | 702,337 | 888,906 | +26.6% | $188.4M |
| SCHRODER INVESTMENT MANAGEMENT GROUP | ADD | 295,035 | 417,715 | +41.6% | $88.8M |
| BNP PARIBAS FINANCIAL MARKETS | ADD | 270,281 | 395,245 | +46.2% | $83.8M |
| Qube Research & Technologies Ltd | TRIM | 734,714 | 343,398 | -53.3% | $72.8M |
| MACKENZIE FINANCIAL CORP | DOUBLED | 126,510 | 333,295 | +163.5% | $70.6M |
| BALYASNY ASSET MANAGEMENT L.P. | DOUBLED | 2,898 | 275,371 | +9402.1% | $58.4M |
| MARSHALL WACE, LLP | ADD | 200,278 | 269,760 | +34.7% | $57.2M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
17 insiders, 50 transactions. Net -$14.4M — $0.00 bought, $14.4M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | Davis J. E. | CEO and President | SELL | 10,000 | $242.72 | $2.4M |
| Aug 28, 2026 | PREVOZNIK MICHAEL E | SVP & General Counsel | EXERCISE | 22,677 | $112.17 | $2.5M |
| Aug 28, 2026 | PREVOZNIK MICHAEL E | SVP & General Counsel | SELL | 16,010 | $242.88 | $3.9M |
| Aug 28, 2026 | PREVOZNIK MICHAEL E | SVP & General Counsel | SELL | 6,237 | $243.63 | $1.5M |
| Aug 28, 2026 | PREVOZNIK MICHAEL E | SVP & General Counsel | SELL | 430 | $244.51 | $105.1K |
| Aug 28, 2026 | PREVOZNIK MICHAEL E | SVP & General Counsel | GIFT | 1,000 | — | — |
| Jul 28, 2026 | DELANEY MARK E | SVP & Chief Commercial Officer | SELL | 1,600 | $235.18 | $376.3K |
| Jul 22, 2026 | Plewman Patrick | SVP for Diagnostic Services | L | 46 | $206.81 | $9.5K |
| Jul 22, 2026 | MAIN TIMOTHY L | Director | L | 21 | $206.81 | $4.3K |
| Jul 22, 2026 | CARTER ROBERT B | Director | L | 11 | $206.80 | $2.3K |
Congressional trades
DGX trades disclosed by members of Congress, with disclosure delay.
3 members · 2 buys / 2 sells
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Mar 27, 2026 | Alan Armstrong | R | SENATE | BUY | $1,001 - $15,000 | Quest Diagnostics Inc | Jul 22, 2026(117d) |
| Oct 30, 2025 | Julie Johnson | D | HOUSE | SELL | $1,001 - $15,000 | Quest Diagnostics Inc | Aug 6, 2026(281d) |
| Oct 30, 2025 | Julie Johnson | D | HOUSE | BUY | $1,001 - $15,000 | Quest Diagnostics Inc | Aug 6, 2026(281d) |
| Mar 10, 2025 | Carol Miller | R | HOUSE | SELL | $15,001 - $50,000 | Quest Diagnostics Inc | Aug 14, 2026(523d) |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for DGX.
Shares short
3,600,559
Settlement Sep 15, 2026
Change vs prior
+4.5%
Semi-monthly cycle
Days to cover
3.7
At avg daily volume
Of shares outstanding
≈3.3%
Estimate — not % of float
All DGX filing & press-release reports (9)
- PRESS-RELEASE reportSep 9, 2026
- CLUSTER reportSep 4, 2026
- 8-K reportJul 23, 2026
- COURT-RULING reportJul 3, 2026
- 8-K reportMay 8, 2026
- 8-K reportApr 21, 2026
- CLUSTER reportMar 11, 2026
- CLUSTER reportMar 6, 2026
- CLUSTER reportMar 4, 2026